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Abstract
OBJECTIVES: The aim of this study was to evaluate the risk factors associated with Contegra graft (Medtronic Minneapolis, MN, USA) infec-
tion after reconstruction of the right ventricular outﬂow tract.
METHODS: One hundred and six Contegra grafts were implanted between April 1999 and April 2010 for the Ross procedure (n = 46), iso-
lated pulmonary valve replacement (n = 32), tetralogy of Fallot (n = 24), double-outlet right ventricle (n = 7), troncus arteriosus (n = 4),
switch operation (n = 1) and redo of pulmonary valve replacement (n = 2). The median age of the patients was 13 years (range 0–54 years).
A follow-up was completed in all cases with a median duration of 7.6 years (range 1.7–12.7 years).
RESULTS: There were 3 cases of in-hospital mortality. The survival rate during 7 years was 95.7%. Despite the lifelong endocarditis prophy-
laxis, Contegra graft infection was diagnosed in 12 (11.3%) patients at a median time of 4.4 years (ranging from 0.4 to 8.7 years). Univariate
analysis of preoperative, perioperative and postoperative variables was performed and the following risk factors for time to infection were
identiﬁed: female gender with a hazard ratio (HR) of 0.19 (P = 0.042), systemic-to-pulmonary shunt (HR 6.46, P < 0.01), hypothermia (HR
0.79, P = 0.014), postoperative renal insufﬁciency (HR 11.97, P = 0.015) and implantation of permanent pacemaker during hospitalization
(HR 5.29, P = 0.075). In 2 cases, conservative therapy was successful and, in 10 patients, replacement of the infected valve was performed.
The Contegra graft was replaced by a homograft in 2 cases and by a new Contegra graft in 8 cases. Cox’s proportional hazard model indi-
cated that time to graft infection was signiﬁcantly associated with tetralogy of Fallot (HR 0.06, P = 0.01), systemic-to-pulmonary shunt (HR
64.71, P < 0.01) and hypothermia (HR 0.77, P < 0.01).
CONCLUSION: Contegra graft infection affected 11.3% of cases in our cohort, and thus may be considered as a frequent entity that can be
predicted by both intraoperative and early postoperative factors. After the diagnosis of infection associated with the Contegra graft was
conﬁrmed, surgical treatment was the therapy of choice.
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INTRODUCTION
Bovine jugular vein conduit (Contegra; Medtronic, Inc., Minneapolis,
MN, USA) is routinely used for reconstruction of the right ven-
tricular outﬂow tract (RVOT) nowadays, as part of the repair of
congenital heart defects and/or as a replacement for the pulmon-
ary valve in the Ross procedure. In 1999, the Contegra graft was
ﬁrst proposed as a substitute for the reconstruction of the continu-
ity between RVOT and pulmonary arteries. Since then, due to its
encouraging initial clinical results [1–3], this xenograft gained wide
popularity and acceptance in cardiac surgical practice.
Early and mid-term clinical results of the Contegra graft are
controversial. The initial enthusiasm over mid-term results in early
reports [4, 5] was soon replaced by more realistic data on stenosis
and/or conduit insufﬁciency [6, 7]. Although numerous retrospect-
ive trials have evaluated clinical outcomes following Contegra
graft implantation, no report exists that deals with postoperative
incidence and predictive factors for Contegra graft infection, apart
from some case reports.
The aim of this retrospective study was to describe the inci-
dence and predictive factors for postoperative Contegra graft in-
fection after RVOT reconstruction in a heterogeneous mix of
patients (age range 0–54 years).
MATERIALS ANDMETHODS
Patient population and data collection
Institutional review board approval and informed patient consent
were obtained for this retrospective study. Data for all implanted
Contegra grafts for reconstruction of the RVOT between April
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1999 and April 2010 were retrospectively collected from
University Hospital Lausanne.
Data from our institutional database were collected for variables
such as age, sex, weight, type of surgical intervention, type of con-
genital malformation, congestive cardiomyopathy, history of
myocardial ischaemic disease, smoking, hypertension, history of
previous intervention, preoperative ejection fraction, New York
Heart Association (NYHA) state, RVOT pathology and renal func-
tional impairment. Procedural data were also collected on the use
of cardiopulmonary bypass, the degree of hypothermia and con-
comitant procedures. Postoperative parameters included emer-
gency exploration due to haemodynamic instability, hospital
mortality, length of hospital stay, intensive care unit (ICU) stay, in-
tubation time and incidence of major cardiovascular events (e.g.
myocardial ischaemic event, stroke, death for cardiac reasons).
The haemodynamic status of patients with an implanted Contegra
was evaluated by transthoracic echocardiogram upon discharge
from hospital.
The follow-up ended on 15 April 2012 and was performed via
phone calls to the patients, referred physicians and referred
cardiologists.
All patients were started on aspirin for antiplatelet therapy post-
operatively for 6 weeks, and received a lifelong antibiotic prophy-
laxis for the prevention of endocarditis. The median follow-up was
7.6 years with a range between 1.7 and 12.7 years, and was com-
pleted in 100% (n = 106) of cases.
Conduit endocarditis was deﬁned according to the Duke criteria
[8], with consideration of the following factors: new cardiac murmur
over the second left intercostal space, evidence of mobile mass and/
or destruction of leaﬂets in the Contegra graft, positive haemoculture
and presence of systematic inﬂammatory response syndrome [9].
Prophylactic antibiotic therapy
According to our institutional protocol, oral prophylaxis was
started 24 h before the operation, followed by a single intravenous
premedication dose. A second single dose was introduced during
the priming of the cardiopulmonary bypass. Postoperative antibiotic
therapy was continued intravenously until the drains were removed
(usually 48–72 h after the operation). Cefaclor and cefadroxil were
used as oral antibiotics, and cefotiam was used intravenously.
Statistics
Categorical variables are summarized with number (percent) and
compared across groups using the χ2 test or the Fisher’s exact test.
Continuous variables are presented as medians (interquartile
range) and compared across groups using a non-parametric ver-
sion of the Kolmogorov–Smirnov test. Time-to-event end points
are summarized using a Kaplan–Meier estimate and compared
across groups with a Cox proportional hazard model. The end
point of interest in the present study is time-to-Contegra infection.
A Cox proportional hazard model was used to model time-
to-Contegra infection, with deaths excluded. Selection of statistic-
ally signiﬁcant covariates was carried out into two different ways:
(i) using stepwise methods (i.e. likelihood ratio test) and (ii) calcu-
lating the c-statistic (a generalization of Somer’s D), which is a
measure of the rank correlation between the time to infection
censored response and a series of covariates. All statistical analyses
were performed using the R version 2-15-2 statistical package.
RESULTS
One hundred and six patients were included in this study, of
which 29.2% were females. The median age was 13 years (range
from 0 to 54), and the mean weight was 42.3 kg (ranging between
4.3 and 95.0 kg). In all 106 cases, RVOT reconstruction was per-
formed by implantation of a Contegra graft.
Indications of RVOT reconstruction were as follows: tetralogy of
Fallot (n = 24), Ross procedure (n = 46), troncus arteriosus commu-
nis (n = 4), isolated pulmonary valve stenosis (n = 32), double-
outlet right ventricle (n = 7) and transposition of the great arteries
(n = 3). Closure of ventricular septal defect by patch was per-
formed as a concomitant procedure in 4 cases. Twelve of the 32
cases of isolated pulmonary valve replacement were reoperations
of tetralogy of Fallot, while 20 cases were isolated pulmonary
valve pathologies.
Additionally, prior to Contegra implantation, a systemic-to-
pulmonary shunt (n = 10) and Blalock–Taussig shunt (n = 8) were
carried out. The preoperative characteristics of patients are pre-
sented in Table 1.
All available Contegra graft sizes (10–22 mm) were used in the
patients involved in the study, and the mean size of the implanted
graft was 20 mm. The operative technique has been described in
detail previously [10]. The mean duration of intervention was
304.0 ± 77.5 min, extracorporeal circulation time was 151.4 ± 51.1
min and aortic cross-clamping time was 71.2 ± 34.8 min. The
mean intubation time was 4.8 ± 13.9 days and the mean ICU time
was 9.4 ± 23.0 days. Reoperation due to bleeding was performed
in 12 cases (11.3%). In the postoperative period, major cardiovas-
cular events were as follows: incidence of myocardial ischaemia in
6 cases (5.7%), cerebrovascular events in 2 cases (1.9%) and renal
impairment was registered in 3 cases (2.8%). A permanent pace-
maker was implanted in 4 cases (3.8%) due to a high degree
of atrioventricular block. In-hospital mortality was registered in
3 cases (2.8%) and was of a cardiac cause.
The follow-up was completed in 100% of cases with a median
duration of 7.6 years (ranging 1.7–12.7 years). Mortality during the
follow-up occurred in 2 cases (1.9%) and was of a cardiac cause
(Table 2).
Table 1: Preoperative variables in 106 cases having recon-
struction of RVOT with a Contegra graft
Preoperative variables
Female gender 31 (29.2%)
Age, mean (years) 17.4 ± 16.0
Age > 18 years 38 (35.8%)
Preoperative coronary artery disease 15 (14.2%)
Active smoker 13 (12.3%)
Preoperative renal failure 3 (2.8%)
Hypercholesteraemia 5 (4.7%)
NYHA class > II 33 (31.1%)
LVEF 64.3 ± 9.6%
Preoperative pathology
Tetralogy of Fallot 24 (22.6%)
Double-outlet right ventricle 7 (6.6%)
Truncus arteriosus communis 4 (3.8%)
Isolated pulmonary stenosis 10 (9.4%)
Transposition of great vessels 3 (2.8%)
Isolated aortic valve disease 47 (44.3%)
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Endocarditis of the Contegra graft was diagnosed in 12 patients
(11.3%) and developed at a median time of 4.4 years (range 0.4–
8.7 years). In 2 cases, conservative therapy was successful, and
in 10 patients, replacement of the infected valve was performed.
The Contegra graft was replaced by a homograft in 2 cases and by
a new Contegra graft in 8 cases.
According to Kaplan–Meier analysis, the rates of freedom from
Contegra graft infection were 98.0% at 1 year, 88.% at 5 years and
82.0% at the end of the follow-up (12.7 years) (Fig. 2).
Univariate analysis suggested that time to infection was signiﬁ-
cantly associated with female gender (hazard ratio (HR) 0.19,
P = 0.042), systemic-to-pulmonary shunt (HR 6.46, P < 0.01), hypo-
thermia (HR 0.79, P = 0.014), postoperative renal insufﬁciency (HR
11.97, P = 0.015) and marginally with implantation of a permanent
pacemaker during hospitalization (HR 5.29, P = 0.075).
Cox’s proportional hazard model analysis indicated that the
presence of tetralogy of Fallot signiﬁcantly decreases the risk of in-
fection by 94% (P = 0.01). Risk of infection for participants with sys-
temic to pulmonary shunt is 64.71 times higher than those
without (P < 0.01). In patients with hypothermia, each increase in
temperature by 1°C was found to decrease the risk of infection by
23% (P < 0.01; Fig. 1). Finally, the c-statistic for the time-to-infection
censored variable is estimated at 0.54 (P-value = 37.0%) for ‘Fallot’,
at 0.36 (P-value = 3.5%) for ‘central confection’ and at 0.68
(P-value = 2.7%) for ‘hypothermia’.
Following discharge, all patients underwent a bacterial endocar-
ditis prophylaxis, as suggested by the American Heart Association.
In this matter, the ﬁrst-line antibiotic was Amoxicillin 50 mg/kg
orally. In case of penicillin allergy with exanthema, we propose
Cefuroxim-Axetil 50 mg/kg orally and in case of Penicillin allergy
with urticaria and immediate reaction, we proposed Clindamycin
Table 2: Perioperative incidence of mortality and morbidity
after Contegra graft implantation including follow-up events,
during a maximum follow-up period of 12.7 years
Perioperative variables
Renal impairments 3 (2.8%)
Reoperation because of bleeding 12 (11.3%)
Neurological event 2 (1.9%)
Mediastinitis 1 (0.9%)
Permanent pacemaker implantation 4 (3.8%)
Myocardial ischaemic event 6 (5.7%)
In-hospital mortality 3 (2.8%)
Cardiac cause of death 3 (2.8%)
Follow-up events
Mortality 2 (1.9%)
Cardiac cause of death 2 (1.9%)
Infection of Contegra graft 12 (11.3%)
Reoperation because of Contegra graft infection 10 (9.4%)
Reoperation because of structural deterioration of
Contegra graft
10 (9.4%)
Angioplasty of the distal anastomosis of Contegra graft 6 (5.7%)
Figure 1: Association between grade of intraoperative hypothermia and time to Contegra graft infection. Each increase in temperature towards the normal core tem-
perature decreases the hazard of infection by 23%.
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20 mg/kg orally. In the follow-up, general physicians found no as-
sociation between the incidence of infection and invasive proce-
dures such as dental intervention, respiratory tract procedures or
gastrointestinal invasive diagnostic procedures.
Of the 12 patients with encodarditis, 1 was treated for septicaemia
caused by an unknown pathogen 1 month preceding endocarditis
and 2 patients prior to infection had dental treatment without
prophylaxis. The germ identiﬁed in these 2 cases was streptococcus
epidermidis. One patient underwent a dental extraction under
prophylaxis (the germ isolated was staphylococcus saprophyticus).
One subject was hospitalized due to mediastinitis. In addition, one
subject was found to have Streptococcus salivarius, and another
Streptococcus viridans, as the pathogen responsible for their endocar-
ditis without any recent history of dental intervention or other in-
fection, as determined by haemoculture. Fungal infection was not
identiﬁed in any of these cases.
CONCLUSION
Since the introduction of the Contegra graft to daily clinical prac-
tice in 1999, it appeared that a reliable substitute for homografts
in the reconstruction of the RVOT in complex congenital heart dis-
eases had been found. Owing to its ready availability and wide
range of sizes, the Contegra graft was, and still is, of great interest
to clinically active cardiac surgeons. Controversy regarding graft
durability in long- and mid-term time periods does exist. It seems
that the age, size and extra-anatomical position of the graft are in-
dependent predictive factors for graft failure. Age and graft size
show an inverse relationship and are actually an indication of the
overgrowth of the graft [3, 11]. Graft overgrowth is indeed a
subject of intensive debate in the recent literature. The fact is that
the recent literature on the Contegra graft is extensive and, on ﬁrst
gaze, one would have the impression that every facet of its clinical
implication in RVOT reconstruction was evaluated. However, with
the exception of a few case reports [12, 13], no reports on
Contegra graft infection currently exist. This lack of evidence may
be due to the limited clinical signs and haemodynamic effects of
the deteriorated valve on right ventricular function.
This report has evaluated the incidence and the predictive
factors for Contegra graft infections for the ﬁrst time. The inci-
dence rate of graft infection was 11.3% (12 patients out of 106),
and the risk rate of infection by the end of the ﬁrst year after
surgery was 1.0%. After this period, the risk rate of infection rose
by 2.1% per year during the 12.7 years of follow-up.
It is well known that heart valve prostheses represent a strong
risk factor for endocarditis in the postoperative period. The overall
risk rate of endocarditis in patients who underwent aortic valve re-
placement ranges from 1 to 5% in the ﬁrst year after implantation,
and is 1% per year thereafter. Risk factors such as gender, reo-
peration and mechanical prosthesis were identiﬁed. The risk of
endocarditis linked to prosthesis emerges between 3 and 12
months after surgery and then a low constant risk rate of 0.5%
per year occurs thereafter [14].
In contrast, in the case of the Contegra graft, the probability of
infection in the ﬁrst year following implantation was 1.0%. Two
peaks of infection occurrence were noted, the ﬁrst of which is
between the ﬁrst and second years, when the probability of infec-
tion increases from 2.0 to 5.0%, and the second between the
fourth and ﬁfth years, when the probability of infection increases
from 6.2 to 11.9% (Fig. 2). The results of the present investigation
suggest that perioperative factors do not play a major role in this
Figure 2: Kaplan–Meier evaluations for the probability of Contegra graft infection during the follow-up of 12.7 years. At the end of the follow-up, the cumulative risk
for infection is estimated to be at 18%. Two peaks of infection rate are observed: the ﬁrst is between the ﬁrst and the second year and the second is between the
fourth and the ﬁfth year of the follow-up.
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pathology, since the incidence of Contegra infection in the ﬁrst
year is relatively low. However, gender, grade of hypothermia,
performance of a central shunt and implantation of a permanent
pacemaker during hospitalization were identiﬁed as independent
predictive factors for Contegra graft infection. Surprisingly, factors
such as ICU stay, intubation time and reintervention for bleeding
were not identiﬁed as risk factors for Contegra graft infections.
These results may be explained due to the relatively small cohort
included in the study. The female gender as a predictive factor for
prosthesis endocarditis is in contrast to recent results from other
studies, where the female gender has been identiﬁed as a protect-
ive element for endocarditis. The development of native as well as
prosthetic valve endocarditis was found to be two times higher in
males compared with females [15, 16].
The inﬂuence of permanent pacemaker implantation and
central shunt as predictive factors for infection is not surprising.
The central shunt as a predictive factor is related to the theory of
high velocity ﬂow and turbulence in mechanical erosion of the
endothelium [17, 18]. The same phenomenon of mechanical
damage to the endothelium may be supposed in cases of pace-
maker implantations. However, the inﬂuence of perioperative
hypothermia on infection is less clear. It can be hypothesized that
hypothermia in combination with cardiopulmonary bypass pro-
vokes endothelial apoptosis as well as altered haemodynamics of
the pulmonary artery [19]. Endothelial damage may contribute to
apposition of thrombi to the vessel wall; thrombi that later serve
as an anchoring substrate for infection. Considering damage to
the endothelium as a trigger factor for the development of endo-
carditis, it could be expected that the incidence of infection would
peak in the early postoperative period, as this is the case in aortic
valve prosthesis implantation [14]. In contrast, our results showed
two peaks; the ﬁrst was registered between the ﬁrst and second
postoperative years and the second between the fourth and ﬁfth
postoperative years (Fig. 2). The reason for this late appearance of
infection is not clear, and it is likely that the cause is multifactorial.
The initial endothelial damage that is either due to mechanical
factors (e.g. pacemaker implantation), ischaemia (e.g. hypother-
mia) or turbulence (e.g. central shunt) contributes to the appos-
ition of initial thrombi to the vessel wall. These thrombi may serve
as an anchoring substrate for bacterial colonization. It should be
noted that the low-ﬂow, low-pressure conditions do not contrib-
ute to the wash-out of the thrombi apposition, as would be the
case in the left-sided circulation. Consequently, it is probable that
thrombi generated in the perioperative period, and ﬁbrous appo-
sitions, would stay attached to the vessel wall for longer. Later,
these thrombi may be strongly prone to becoming a host structure
due to transient bacteraemia and may, therefore, be a cause for
prosthesis infection.
This theory is suggested since a common factor identiﬁed in
this study was mechanical, haemodynamical or chemical damage
to the endothelium. To our knowledge, this is the ﬁrst study to in-
vestigate Contegra graft infection over a long time period. With an
incidence of 11.3%, Contegra graft infection is a serious complica-
tion that in the majority of cases required surgical intervention.
Predictive factors were identiﬁed, but the exact mechanism of the
Contegra endocarditis is still unclear. It is obvious that, for such a
frequent complication, it is essential to explore the pathological
mechanism in detail. In particular, the cause of the late appearance
is not clear. Only further clinical and experimental research will
provide a deeper insight to help prevent this complication.
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